MaterniT21 validation for sex chromosome aneuploidy • MPSS technology for NIPT allows for genome wide analysis, and thus opportunity for expansion to other clinically relevant fetal chromosomal abnormalities, like sex chromosome aneuploidy • 411 NIPT samples • 96.2% sensitivity and 99.7% specificity overall (combined SCAs) • NIPT identification of the most